ST Notch announced that in the first half of 2026, it achieved revenue of 1,140 billion yuan, an increase of 8.72% over the previous year. The oligonucleotide API production workshop at the Lianyungang factory was officially put into operation, and the oligonucleotide production capacity jumped to tonnage; the small-volume injection production line passed the drug GMP compliance inspection. The 2025 annual equity distribution was implemented during the reporting period, with a cash dividend of 0.35 yuan per share based on a total share capital of 31605,1897 shares, for a total of 111 million yuan, accounting for 33.28% of the net profit due to mother in 2025. In June 2026, the third phase of restricted stock ownership was completed, and 764,400 shares were vested to 58 incentive recipients.

ST Notch announced that in the first half of 2026, it achieved revenue of 1,140 billion yuan, an increase of 8.72% over the previous year. The oligonucleotide API production workshop at the Lianyungang factory was officially put into operation, and the oligonucleotide production capacity jumped to tonnage; the small-volume injection production line passed the drug GMP compliance inspection. The 2025 annual equity distribution was implemented during the reporting period, with a cash dividend of 0.35 yuan per share based on a total share capital of 31605,1897 shares, for a total of 111 million yuan, accounting for 33.28% of the net profit due to mother in 2025. In June 2026, the third phase of restricted stock ownership was completed, and 764,400 shares were vested to 58 incentive recipients.